Amylyx Pharmaceuticals (AMLX) Equity Ratio (2021 - 2026)

Amylyx Pharmaceuticals' Equity Ratio history runs 6 years deep, the most recent figure standing at 0.93 for Q1 2026.

• In Q1 2026, Equity Ratio rose 1.47% year-over-year to 0.93; the TTM figure through Mar 2026 stood at 0.93 (up 1.47% YoY), while the FY2025 annual figure was 0.92, up 7.85% from the prior year.
• Equity Ratio was 0.93 for Q1 2026 at Amylyx Pharmaceuticals, up from 0.92 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.93 in Q1 2026 to a low of 0.78 in Q1 2024.
• Historically, Equity Ratio has averaged 0.86 across 5 years, with a median of 0.86 in 2025.
• The sharpest annual moves came in 2022 and 2024: Equity Ratio soared 160.79% in 2022, then declined 12.73% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.87 in 2022, then retreated by 3.73% to 0.84 in 2023, then climbed by 1.59% to 0.85 in 2024, then advanced by 7.85% to 0.92 in 2025, then increased by 1.38% to 0.93 in 2026.
• The last three Equity Ratio figures came in at 0.93 (Q1 2026), 0.92 (Q4 2025), and 0.92 (Q3 2025), per Business Quant data.